GSK's Bioelectronics R&D unit is pursuing a relatively new scientific field that could one day result in a new class of medicines that would not be pills or injections but miniaturised, implantable devices.

GSK has invested $7.7 million in a new pilot vaccine facility with the hope Australian manufacturing innovation could reduce cost of vaccination in developing world.

Back to top